KOSDAQBiotech & Pharma099430

BioPlus

₩3,165▲ 1.61%2026-11-18 close
Market Cap
₩195.1B
Turnover
₩300M
Volume
100K
Shares out.
61.6M
PER
14.8×
PBR
1.0×
EPS
₩203
Dividend Yield
2.33%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩70 per share · Prices as of the 2026-11-18 close

01

Report overview

Testing the profit recovery after the Eumseong plant ramp-up

BioPlus posted record revenue in 2025 while operating profit fell, and its 2026 nine-month revenue and operating profit have both risen, so whether the profit recovery holds is the key point to verify.

  1. 1

    2025 revenue rose 36.9% year on year to KRW 90.9 billion, the largest year in 2022–2025, while operating profit fell 36.6% to KRW 15 billion.

  2. 2

    Nine-month 2026 revenue reached KRW 79.19 billion, up 17% year on year, and operating profit reached KRW 18.09 billion, up 29%, with a cumulative operating margin of 22.8%, as disclosed on 16 November 2026.

  3. 3

    Net income attributable to owners peaked at KRW 6.69 billion in Q1 2026 and then fell for two straight quarters, moving in the opposite direction from operating profit.

  4. 4

    The company has set a 2026 target of KRW 120 billion in revenue and operating profit in the KRW 30 billion range, which requires a much larger fourth quarter than the nine-month run rate.

  5. 5

    CEO Jung Hyun-gyu and other executives bought treasury shares on the open market in January and February 2026, and the company also announced expanded shareholder returns including dividends.

02

Business structure

BioPlus is a medical aesthetics and cosmetics company centered on hyaluronic acid (HA) fillers. It was founded in 2003, listed on KOSDAQ in 2021, and in 2025 expanded its scope by establishing and acquiring a stake in BioPlus USA Inc.

Exports are a defining feature: the export share was 72% in 2024, and the company said it would move away from indirect exports through original development manufacturing (ODM) and push direct exports from 2025.

Fillers remain the core revenue base, and the company is widening its range into medical aesthetics, cell boosters and bio skincare based on its growth factor platform HUGRO and recombinant collagen type III technology. On the pharmaceutical side, an obesity and diabetes drug business has been added.

According to an April 2025 report, the company targeted an export approval for a Saxenda generic within that year, and planned to file a clinical phase 3 trial application in 2027 and a US marketing application in 2028 for a patch-type biobetter of Wegovy.

Its recombinant botulinum toxin was in preclinical development as of late 2024, with a phase 1 trial as the goal. On production, the company said at an investor relations event that the Eumseong Bio Complex, into which about KRW 160 billion was invested, is complete.

Competition overlaps with domestic filler and toxin makers, and in toxins it is compared with players such as Hugel.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.1B₩4.9B20.3%
2025Q4₩23.2B₩1B4.2%
2026Q1₩26.5B₩5.7B21.3%
2026Q2₩25.4B₩6.2B24.6%
2026Q3₩27.3B₩6.2B22.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩56.7B₩25.3B₩21.1B44.6%18.7%27.5%
2023₩65B₩28B₩25.6B43.1%20.0%25.2%
2024₩66.4B₩23.7B₩14.2B35.6%10.6%78.9%
2025₩90.9B₩15B₩15B16.5%8.6%46.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual results from 2022 to 2025 show a company whose revenue grew while its margins compressed. Revenue rose from KRW 56.7 billion in 2022 to KRW 65 billion in 2023 (up 14.7%) and KRW 66.4 billion in 2024 (up 2.1%), then reached KRW 90.9 billion in 2025 (up 36.9%), the largest year in the period.

The company described 2025 as a year of record sales. Operating profit peaked at KRW 28 billion in 2023 (up 10.9%), then fell to KRW 23.7 billion in 2024 (down 15.6%) and KRW 15 billion in 2025 (down 36.6%), declining for two consecutive years.

The operating margin moved from 44.6% in 2022 and 43.1% in 2023 to 35.6% in 2024 and 16.5% in 2025. The company attributed the 2025 decline not to weaker profitability but to strategic investment, including spending on the Eumseong new plant, more than doubling recurring R&D, and higher marketing and hiring costs.

The 2024 decline reflected the sales structure reorganization and tighter ODM trading terms that the company began in the first half of the year. Net income attributable to owners was KRW 25.6 billion in 2023, KRW 14.2 billion in 2024 (down 44.7%) and KRW 15 billion in 2025 (up 6.0%).

Consolidated net income including non-controlling interests was KRW 20 billion in 2025, a different figure.

The debt ratio rose from 25.2% in 2023 to 78.9% in 2024 and fell to 46.2% at the end of 2025, when total equity was KRW 195 billion, of which KRW 174.8 billion belonged to owners of the parent, and total liabilities were KRW 90.1 billion.

Operating cash flow was KRW 13.4 billion in 2022, KRW 16 billion in 2023, KRW 22.3 billion in 2024 and KRW 14.7 billion in 2025.

Quarterly, operating profit was KRW 4.88 billion in Q3 2025 and KRW 963 million in Q4 2025, a fall of 80.3% quarter on quarter, before recovering to KRW 5.65 billion in Q1 2026, KRW 6.25 billion in Q2 and KRW 6.19 billion in Q3 2026.

Q3 2026 operating profit rose 26.9% year on year, yet net income attributable to owners fell 42.7% to KRW 1.79 billion, so the two moved in opposite directions. Which items drove that gap is a point to check in the periodic report details.

05

Industry analysis

BioPlus's core market is medical aesthetics, covering fillers and toxins. In this market, the speed of country-by-country product approvals and the securing of distribution partners drive growth.

The company obtained a Brazilian ANVISA marketing approval for a filler in June 2023 and began supplying through its local partner Cimed. Because overseas sales make up a large share, approval expansion translates directly into export performance, as the 72% export share in 2024 illustrates.

On production, the company said its Eumseong bio complex includes fully automated upstream lines that support cost competitiveness.

The nine-month 2026 operating margin of 22.8%, up from 20.7% in the same period of 2025, points to improving scale and cost structure, but it remains below the 40%-plus margins of 2022 and 2023.

The obesity drug market is expanding with demand for GLP-1 class treatments, drawing generic and biobetter development, and the company's approval timelines and pricing pressure depend on regulators and competitors beyond its control.

In toxins it competes with domestic players such as Hugel, and BioPlus is trying to differentiate with a recombinant toxin candidate.

06

Outlook

The company set a 2026 target of KRW 120 billion in revenue and an operating profit in the KRW 30 billion range, with an operating margin above 30%, as reported in February 2026.

Nine-month 2026 revenue of KRW 79.19 billion means fourth-quarter revenue of roughly KRW 40.8 billion would be needed to hit the target, about 1.5 times the Q3 level of KRW 27.3 billion.

Reaching operating profit in the KRW 30 billion range would require roughly KRW 12 billion in the fourth quarter, nearly double the Q3 2026 figure of KRW 6.19 billion. The company said the Eumseong plant investment is complete, reducing fixed-cost burden, and that it has entered a phase of returning that investment.

It also plans to raise the overseas share of revenue above 90%, and it is diversifying into obesity drugs and a bio foundry business. Its long-term goal of KRW 1 trillion in revenue and KRW 500 billion in net income for 2030 was stated in an April 2025 report, and no later reaffirmation has been confirmed.

Whether the company's outlook matches the quarterly trend is the next point to check, and the 2026 fourth-quarter preliminary results and the 2026 annual report will confirm whether the annual target and operating margin were met.

07

Valuation

PER
14.8×
PBR
1.0×
ROE
7.1%
EPS
₩203
BPS
₩2,945
Dividend per share
₩70

The share price is close to the book value attributable to owners of the parent at the end of 2025, so the premium over net asset value is modest. Quarter-end price-to-book ratios were in the mid-2x to low-3x range from September 2024 to September 2025, so the current multiple sits well below that earlier band.

The price-to-earnings multiple is highly sensitive to the earnings base, since net income attributable to owners fell 44.7% in 2024 and 42.7% in Q3 2026 on a year-on-year basis, so the same share price can look different depending on the earnings level.

The dividend yield was in the 1% range in 2022 and 2023 and below 1% in 2024, and the company's 2025 announcement of an expanded dividend could change the shareholder return level.

Compared with filler and cosmetics peers, the market value relative to earnings reflects the volatility of those earnings, and the multiple will read differently as quarterly results accumulate.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Nine-month profit recovery

Nine-month 2026 revenue reached KRW 79.19 billion, up 17% year on year, and operating profit reached KRW 18.09 billion, up 29%. The cumulative operating margin was 22.8%, 2.1 percentage points above the 20.7% of the same period in 2025. Profit growth outpacing revenue growth contrasts with the 2025 operating profit decline.

Plant investment complete, fixed-cost burden easing

The company said the Eumseong Bio Complex, into which about KRW 160 billion was invested, is complete, reducing fixed costs and entering a phase of investment recovery. It cited automated upstream lines and prefilled syringe production as cost advantages. These are the company's own grounds for an operating margin recovery.

Global network and executive share purchases

The company said it would expand overseas supply of its cost-competitive products through a network in more than 80 countries. CEO Jung Hyun-gyu and other executives bought treasury shares on the open market in January and February 2026, which the company described as a signal of confidence in profitability. Shareholder return measures including a dividend increase were announced in 2025.

09

Bear factors

How far the operating margin can recover

The operating margin fell from 44.6% in 2022 to 16.5% in 2025. The company called this a temporary effect of strategic investment, but quarterly margins in 2026 remain below the 40-plus percent levels of 2022 and 2023. Whether margins return to that range is a question for future disclosures.

Consecutive declines in net income attributable to owners

Net income attributable to owners peaked at KRW 6.69 billion in Q1 2026 and then fell to KRW 2.03 billion in Q2 and KRW 1.79 billion in Q3, a two-quarter decline. Q3 2026 net income attributable to owners fell 42.7% year on year while operating profit rose, and the trailing four-quarter total is KRW 12.5 billion.

Fourth-quarter load against the target

The company set targets of KRW 120 billion in 2026 revenue and operating profit in the KRW 30 billion range. Given nine-month revenue of KRW 79.19 billion, the fourth quarter would need about KRW 40.8 billion.

Operating profit would need roughly KRW 12 billion in that quarter, close to double the Q3 figure of KRW 6.19 billion.

10

Risk factors

Export, currency and partner dependence

The export share was 72% in 2024, so most revenue comes from overseas. Currency moves and country-level approval or regulatory changes could feed directly into results. Brazilian supply ran through local partner Cimed as of 2023, so changes in partner volumes are another variable.

Pipeline approval and trial timing

Pipeline assets in obesity treatment and toxins can slip depending on trial and approval timing. The US filing for the patch-type biobetter was planned for 2028, and the toxin phase 1 target comes from older reporting. Any delay would keep growth expectations centered on fillers and cosmetics.

Convertible bonds and earnings volatility

In February 2026 the company announced plans to exercise a call option to resolve convertible bond overhang concerns. Net income attributable to owners fell 44.7% in 2024, and in Q3 2026 it moved opposite to operating profit. Wide quarterly swings in earnings could make share price multiples swing with revisions.

11

What to watch next

  1. Around mid-February 2027 (estimate based on the 13 February 2026 preliminary release last year)

    Check the fourth-quarter 2026 preliminary results against the KRW 120 billion revenue target and the fourth-quarter operating profit needed. The fourth-quarter step-up relative to the nine-month pace will determine whether the target was reached.

  2. Late March 2027 (annual report filing deadline)

    The 2026 annual report will confirm the full-year operating margin and net income attributable to owners, along with the reasons for the gap versus operating profit. Details of the expanded dividend should also become clearer around this time.

  3. Around mid-May 2027 (Q1 quarterly report filing deadline)

    Check whether the Q1 2027 operating margin and net income attributable to owners recover relative to the Q1 2026 peak. Whether the two-quarter decline ends will be a reference point for judging profit recovery.

  4. After the December 2026 year-end, at the 2027 shareholder meeting

    Track progress on the shareholder return plan announced in 2025 and on the CB call option. Dilution risk and the scale of dividend payments are the items to watch for their effect on shareholder value.

12

Overall view

BioPlus recorded record 2025 revenue of KRW 90.9 billion, while operating profit fell 36.6% to KRW 15 billion, so growth and margins diverged that year. The company attributed this to strategic investment in the Eumseong plant, R&D and marketing.

Operating profit recovered from Q1 2026, and nine-month operating profit rose 29% to KRW 18.09 billion, with a cumulative margin of 22.8%. Net income attributable to owners, however, declined for two straight quarters after its Q1 2026 peak and fell 42.7% year on year in Q3.

The company's 2026 targets of KRW 120 billion in revenue and operating profit in the KRW 30 billion range would require a sharp fourth quarter.

Bullish factors include completed plant investment, the export base and executive share purchases, while bearish factors include an unconfirmed return to 40-plus percent margins, declining owner net income, pipeline timing and convertible bond-related volatility.

The next checkpoints are the 2026 fourth-quarter preliminary results and the 2026 annual report, which will set the annual target and margin outcome.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. pharm.edaily.co.kr
  3. pharm.edaily.co.kr
  4. money2.daishin.com
  5. m.thinkpool.com
  6. news.nate.com
  7. pharmnews.com
  8. geconomy.co.kr
  9. news.nate.com
  10. esgeconomy.com
  11. pharmnews.com
  12. butler.works
  13. edaily.co.kr
  14. supple.kr
  15. investing.com
  16. edaily.co.kr
  17. dailyinvest.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis